Uncover key drivers, emerging technologies, and competitive movements shaping the rare disease clinical trials market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Rare Disease Clinical Trials Market?
The rare disease clinical trials market has expanded rapidly in recent years. This market is anticipated to increase from $13.3 billion in 2025 to $14.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. The growth observed in the past can be attributed to the broadening of orphan drug development initiatives, the rise in regulatory incentives for rare disease research, the establishment of specialized clinical research organizations, heightened collaboration between academia and industry, and improved diagnostic methods for rare diseases.
The rare disease clinical trials market is anticipated to show significant expansion in the upcoming years. It is projected to achieve a value of $21.34 billion by 2030, progressing at a compound annual growth rate (CAGR) of 9.9%. The projected increase during this period can be attributed to factors such as the increasing implementation of virtual and hybrid trials, the growing utilization of AI for trial optimization, the expansion of global rare disease trial networks, the rising demand for accelerated regulatory approvals, and increased investment in rare disease research and development. Noteworthy trends for the forecast period encompass a greater adoption of decentralized clinical trial models, the increasing use of adaptive trial designs, enhanced integration of digital tools for patient recruitment, an expansion in the collection of real-world evidence, and a heightened focus on trial protocols centered around patients.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28311&type=smp
What Drivers Are Supporting Technological Adoption In The Rare Disease Clinical Trials Market?
The future expansion of the rare disease clinical trials market is expected to be propelled by the increasing prevalence of personalized medicine. This approach focuses on tailoring medical treatment to the specific characteristics of each patient, encompassing factors such as genetics, lifestyle, and environment. The rise in personalized medicine is attributed to its capacity to enhance treatment outcomes, as it customizes therapies to individual patient profiles for greater efficacy and safety. Rare disease clinical trials contribute to the advancement of personalized medicine by generating patient-specific insights that inform the development of targeted therapies, precisely adapted to each individual’s unique genetic and molecular profile. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) indicated personalized medicines represented 34% of approvals in 2022, a percentage that further increased to 38% in 2023. Therefore, the growing adoption of personalized medicine is a key factor driving the growth of the rare disease clinical trials market.
Which Segments Are Contributing To The Growth Of The Rare Disease Clinical Trials Market?
The rare disease clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Therapeutic Area: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Disease, Genetic Disorders, Autoimmune And Inflammation, Hematologic Disorders, Musculoskeletal Disorders, Other Therapeutic Areas
3) By Study Design: Interventional, Observational, Expanded Access
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End-Users
Subsegments:
1) By Phase I: First In Human Trials, Dose Escalation Studies, Safety And Tolerability Studies
2) By Phase II: Proof Of Concept Studies, Dose Response Studies, Efficacy And Safety Studies
3) By Phase III: Randomized Controlled Trials, Comparative Effectiveness Studies, Large Scale Multicenter Trials
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Studies, Real World Evidence Studies
What Upcoming Trends Are Likely To Define The Future Path Of The Rare Disease Clinical Trials Market?
Leading companies operating within the rare disease clinical trials market are concentrating on fostering innovation, for example, by adopting a client-centric approach to deliver bespoke trial designs, enhance patient involvement, and accelerate the progression of targeted treatments for rare conditions. A client-centric approach means prioritizing the necessities, aims, and inclinations of biotech and pharmaceutical clients to offer customized and effective clinical trial solutions. As an illustration, in March 2025, Evestia Clinical Limited, a pharmaceutical research company based in the US, was introduced as the new brand identity for EMAS Pharma. This rebranding signifies a strategic move intended to quicken the company’s global expansion. The company is committed to accelerating the development of therapies for rare diseases by furnishing expert-led, personalized clinical trial solutions specifically tailored to the distinct challenges associated with these conditions. This particular focus constitutes a crucial component of its brand identity and its service offerings.
Who Are The Major Companies Operating In The Rare Disease Clinical Trials Market?
Major companies operating in the rare disease clinical trials market are F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, IQVIA Holdings Inc., Laboratory Corporation of America Holdings, ICON plc, Moderna Inc., Charles River Laboratories International Inc., Parexel International Corporation, Revvity Inc., Sarepta Therapeutics Inc., TFS HealthScience, Inventiva S.A., Tonix Pharmaceuticals Holding Corp., SpringWorks Therapeutics Inc., OrphAI Therapeutics Inc., BBCR Consulting LLC, Credevo Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/rare-disease-clinical-trials-global-market-report
Which Region Is Anticipated To See The Fastest Growth In The Rare Disease Clinical Trials Market?
North America was the largest region in the rare disease clinical trials market in 2025. The regions covered in the rare disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Rare Disease Clinical Trials Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=28311&type=smp
Browse Through More Reports Similar to the Global Rare Disease Clinical Trials Market 2026, By The Business Research Company
Rare Neurological Disease Treatment Market Report 2026
Rare Disease Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model